Pieris Pharmaceuticals (NASDAQ:PIRS) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday.

A number of other brokerages have also issued reports on PIRS. ValuEngine lowered Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. HC Wainwright set a $9.00 target price on Pieris Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $9.00.

Shares of Pieris Pharmaceuticals (NASDAQ PIRS) traded down $0.11 during midday trading on Wednesday, hitting $7.23. 683,363 shares of the stock were exchanged, compared to its average volume of 616,662. The firm has a market cap of $328.79, a PE ratio of -9.90 and a beta of -76.07. Pieris Pharmaceuticals has a twelve month low of $1.38 and a twelve month high of $7.59.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. The business had revenue of $3.93 million for the quarter, compared to analysts’ expectations of $1.52 million. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The business’s revenue was up 400.3% compared to the same quarter last year. sell-side analysts anticipate that Pieris Pharmaceuticals will post -0.72 earnings per share for the current fiscal year.

In other news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $5.70, for a total transaction of $841,519.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.05% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Voya Investment Management LLC purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth $100,000. Wells Fargo & Company MN purchased a new position in shares of Pieris Pharmaceuticals during the 3rd quarter worth $105,000. State of Wisconsin Investment Board purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth $132,000. The Manufacturers Life Insurance Company raised its holdings in shares of Pieris Pharmaceuticals by 1,106.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 29,150 shares during the period. Finally, Rhumbline Advisers purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth $184,000. Institutional investors own 50.45% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://theolympiareport.com/2017/12/28/pieris-pharmaceuticals-pirs-rating-increased-to-buy-at-bidaskclub.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.